ClinicalTrials.gg
CompletedNCT02162667Updated Aug 3, 2022Results posted

Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

A Phase 3 interventional study of Trastuzumab in HER2-positive Carcinoma of Breast, sponsored by Celltrion. Completed at 98 sites in 22 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-03.

Sponsored by Celltrion · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
562
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This study will determine whether CT-P6 and Herceptin are equivalent in patients with early-stage breast cancer undergoing neoadjuvant chemotherapy. Our hypothesis is that the pathologic complete response rate will be equivalent in patients treated with neoadjuvant CT-P6 or Herceptin. Patients will receive 8 cycles of neoadjuvant systemic therapy and up to 10 cycles of therapy in the adjuvant setting.

02

Conditions studied

  • HER2-positive Carcinoma of Breast
03

In context

Lead sponsor

Celltrion is the lead sponsor of 77 studies on the registry; 2 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 14 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient who has confirmed and newly diagnosed breast cancer
  • Patient who has clinical stage I, II, or IIIa operable breast cancer according to AJCC (American Joint Committee on Cancer) Breast Cancer Staging 7th edition
  • Patient who has -positive status confirmed locally, defined as 3+ score by IHC (immuno-histochemistry).

Exclusion criteria

Exclusion Criteria:

  • Patient who has bilateral breast cancer
  • Patient who has received prior treatment for breast cancer, including chemotherapy, biologic therapy, hormone therapy, immunotherapy, radiation or surgery, including any prior therapy with anthracyclines.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
562 participants (actual)

Study arms

  • Experimental
    CT-P6

    Drug: Trastuzumab

  • Active comparator
    Trastuzumab

    Drug: Trastuzumab

Interventions

  • Trastuzumab 6mg/kg is ongoing to be administered for both arms after 8mg/kg loading dose.

    Also known as: Herceptin

06

What researchers measure

Primary outcomes

  1. The Percentage of Patients Achieving Pathological Complete Response Defined as the Absence of Invasion Tumor Cells in the Breast and in Axillary Lymph Nodes, Regardless of Ductal Carcinoma in Situ (DCIS)

    Subject who went through Neoadjuvant period completely (24 weeks), will receive surgery within 3-6 weeks after last treatment of neoadjuvant period. The primary endpoint, Pathological complete response, will be assessed using resected bio-specimens collected in breast and axilla during a surgery.

    Time frame: After Neo-adjuvant therapy and Surgery (up to 30 weeks)

Secondary outcomes

  1. The Percentage of Patients Achieving Pathological Complete Response (pCR) of the Breast Regardless of DCIS With Positive or Unknown Nodal Status

    Subject who went through Neoadjuvant period completely (24 weeks), will receive surgery within 3-6 weeks after last treatment of neoadjuvant period. The secondary endpoint, other than pCR of breast and axillary nodes ragardless of DCIS which was primary endpoint, will be assessed using resected bio-specimens collected in breast and axilla during a surgery.

    Time frame: After Neo-adjuvant therapy and Surgery (up to 30 weeks)

  2. The Percentage of Patients Achieving Pathological Complete Response of the Breast and Axillary Nodes With Absence of DCIS

    Subject who went through Neoadjuvant period completely (24 weeks), will receive surgery within 3-6 weeks after last treatment of neoadjuvant period. The secondary endpoint, other than pCR of breast and axillary nodes ragardless of DCIS which was primary endpoint, will be assessed using resected bio-specimens collected in breast and axilla during a surgery.

    Time frame: After Neo-adjuvant therapy and Surgery (up to 30 weeks)

  3. Overall Response Rate (ORR) From Local Review

    The ORR was defined as the proportion of patients with a BOR of CR or PR as assessed by RECIST guideline Version 1.1 during the Nedadjuvant Period.

    Time frame: After Neo-adjuvant therapy (up to 24 weeks)

  4. Disease-free Survival

    Patients who underwent breast surgery were included in the DFS analysis. Disease-free survival was defined as the interval between the date of breast surgery and disease progression, recurrence, or death from any cause, whichever occurred first. Only a recurrence or progression of disease that occurred before beginning another anticancer therapy was regarded as an event.

    Time frame: Up to 3 years from the day of last patient enrollment (during whole study period)

  5. Progression-Free Survival

    Progression-free survival was defined as the interval between randomization and disease progression, recurrence, or death from any cause, whichever occurred first. Only a recurrence or progression of disease that occurred before beginning another anticancer therapy was regarded as an event.

    Time frame: Up to 3 years from the day of last patient enrollment (during whole study period)

  6. Overall Survival

    Overall survival was defined as the interval between randomization and death from any cause.

    Time frame: Up to 3 years from the day of last patient enrollment (during whole study period)

  7. The Number of Patients Who Had Progressive Disease or Recurrence

    If recurrence or progression of disease occurred at any time during the study, the progressed tumor site was recorded in the "recurrence or progression of disease" eCRF page as local, regional, or distant, with diagnostic method and whether positive cytology or histology or not. The resulting recurrence or progression of disease information was summarized as secondary endpoint.

    Time frame: Up to 3 years from the day of last patient enrollment (during whole study period)

  8. Maximum Serum Concentration After Administration (Cmax) in Each Cycle

    Pharmacokinetic samples were collected before study drug (CT-P6 or US-licensed Herceptin) administration (within 15 minutes prior to the beginning of the study drug infusion) and within 15 minutes after the end of the study drug infusion for each cycle during the Neoadjuvant Period. After the completion of treatment, an additional PK sample was collected at the EOT1.

    Time frame: End of each treatment cycles, up to 24 weeks (during neoadjuvant period)

  9. Trough Serum Concentration (Ctrough) in Each Cycle

    Pharmacokinetic samples were collected before study drug (CT-P6 or US-licensed Herceptin) administration (within 15 minutes prior to the beginning of the study drug infusion) and within 15 minutes after the end of the study drug infusion for each cycle during the Neoadjuvant Period. After the completion of treatment, an additional PK sample was collected at the EOT1.

    Time frame: Pre-infusion of cycles 1 to 8 during neoadjuvant period

07

Results

Posted Oct 29, 2019

Participant flow

Neoadjuvant Period
Participant flow — Neoadjuvant Period
MilestoneCT-P6Herceptin
Started278284
Completed264267
Not completed1417
Adjuvant Period
Participant flow — Adjuvant Period
MilestoneCT-P6Herceptin
Started260268
Completed248255
Not completed1213

Outcome measures

PrimaryThe Percentage of Patients Achieving Pathological Complete Response Defined as the Absence of Invasion Tumor Cells in the Breast and in Axillary Lymph Nodes, Regardless of Ductal Carcinoma in Situ (DCIS)

Subject who went through Neoadjuvant period completely (24 weeks), will receive surgery within 3-6 weeks after last treatment of neoadjuvant period. The primary endpoint, Pathological complete response, will be assessed using resected bio-specimens collected in breast and axilla during a surgery.

Time frame:
After Neo-adjuvant therapy and Surgery (up to 30 weeks)
Reported as:
Number · percentage of responders
The Percentage of Patients Achieving Pathological Complete Response Defined as the Absence of Invasion Tumor Cells in the Breast and in Axillary Lymph Nodes, Regardless of Ductal Carcinoma in Situ (DCIS)
percentage of respondersCT-P6Herceptin
The Percentage of Patients Achieving Pathological Complete Response Defined as the Absence of Invasion Tumor Cells in the Breast and in Axillary Lymph Nodes, Regardless of Ductal Carcinoma in Situ (DCIS)46.77 (40.43 to 53.19)50.39 (44.10 to 56.68)
SecondaryThe Percentage of Patients Achieving Pathological Complete Response (pCR) of the Breast Regardless of DCIS With Positive or Unknown Nodal Status

Subject who went through Neoadjuvant period completely (24 weeks), will receive surgery within 3-6 weeks after last treatment of neoadjuvant period. The secondary endpoint, other than pCR of breast and axillary nodes ragardless of DCIS which was primary endpoint, will be assessed using resected bio-specimens collected in breast and axilla during a surgery.

Time frame:
After Neo-adjuvant therapy and Surgery (up to 30 weeks)
Reported as:
Number · percentage of responders
The Percentage of Patients Achieving Pathological Complete Response (pCR) of the Breast Regardless of DCIS With Positive or Unknown Nodal Status
percentage of respondersCT-P6Herceptin
The Percentage of Patients Achieving Pathological Complete Response (pCR) of the Breast Regardless of DCIS With Positive or Unknown Nodal Status4.84 (2.52 to 8.30)4.69 (2.45 to 8.04)
SecondaryThe Percentage of Patients Achieving Pathological Complete Response of the Breast and Axillary Nodes With Absence of DCIS

Subject who went through Neoadjuvant period completely (24 weeks), will receive surgery within 3-6 weeks after last treatment of neoadjuvant period. The secondary endpoint, other than pCR of breast and axillary nodes ragardless of DCIS which was primary endpoint, will be assessed using resected bio-specimens collected in breast and axilla during a surgery.

Time frame:
After Neo-adjuvant therapy and Surgery (up to 30 weeks)
Reported as:
Number · percentage of responders
The Percentage of Patients Achieving Pathological Complete Response of the Breast and Axillary Nodes With Absence of DCIS
percentage of respondersCT-P6Herceptin
The Percentage of Patients Achieving Pathological Complete Response of the Breast and Axillary Nodes With Absence of DCIS39.92 (33.78 to 46.31)41.41 (35.31 to 47.71)
SecondaryOverall Response Rate (ORR) From Local Review

The ORR was defined as the proportion of patients with a BOR of CR or PR as assessed by RECIST guideline Version 1.1 during the Nedadjuvant Period.

Time frame:
After Neo-adjuvant therapy (up to 24 weeks)
Reported as:
Number · percentage of responders
Overall Response Rate (ORR) From Local Review
percentage of respondersCT-P6Herceptin
Overall Response Rate (ORR) From Local Review84.27 (79.14 to 88.57)83.98 (78.91 to 88.26)
SecondaryDisease-free Survival

Patients who underwent breast surgery were included in the DFS analysis. Disease-free survival was defined as the interval between the date of breast surgery and disease progression, recurrence, or death from any cause, whichever occurred first. Only a recurrence or progression of disease that occurred before beginning another anticancer therapy was regarded as an event.

Time frame:
Up to 3 years from the day of last patient enrollment (during whole study period)
Reported as:
Number · proportion of participants
Disease-free Survival
proportion of participantsCT-P6Herceptin
1 year0.95 (0.91 to 0.97)0.96 (0.93 to 0.98)
2 years0.87 (0.81 to 0.90)0.89 (0.85 to 0.92)
3 years0.82 (0.77 to 0.87)0.82 (0.75 to 0.88)
SecondaryProgression-Free Survival

Progression-free survival was defined as the interval between randomization and disease progression, recurrence, or death from any cause, whichever occurred first. Only a recurrence or progression of disease that occurred before beginning another anticancer therapy was regarded as an event.

Time frame:
Up to 3 years from the day of last patient enrollment (during whole study period)
Reported as:
Number · proportion of participants
Progression-Free Survival
proportion of participantsCT-P6Herceptin
1 year0.99 (0.97 to 1.00)0.98 (0.95 to 0.99)
2 years0.90 (0.86 to 0.94)0.93 (0.89 to 0.95)
3 years0.82 (0.77 to 0.87)0.87 (0.82 to 0.90)
SecondaryOverall Survival

Overall survival was defined as the interval between randomization and death from any cause.

Time frame:
Up to 3 years from the day of last patient enrollment (during whole study period)
Reported as:
Number · proportion of participants
Overall Survival
proportion of participantsCT-P6Herceptin
1 year1.00 (1.00 to 1.00)1.00 (0.97 to 1.00)
2 years0.98 (0.95 to 0.99)0.98 (0.96 to 0.99)
3 years0.95 (0.91 to 0.97)0.94 (0.90 to 0.96)
SecondaryThe Number of Patients Who Had Progressive Disease or Recurrence

If recurrence or progression of disease occurred at any time during the study, the progressed tumor site was recorded in the "recurrence or progression of disease" eCRF page as local, regional, or distant, with diagnostic method and whether positive cytology or histology or not. The resulting recurrence or progression of disease information was summarized as secondary endpoint.

Time frame:
Up to 3 years from the day of last patient enrollment (during whole study period)
Reported as:
Number · participants
The Number of Patients Who Had Progressive Disease or Recurrence
participantsCT-P6Herceptin
Overall Period4135
Neoadjuvant Period12
Adjuvant Period53
Follow-up Period3530
SecondaryMaximum Serum Concentration After Administration (Cmax) in Each Cycle

Pharmacokinetic samples were collected before study drug (CT-P6 or US-licensed Herceptin) administration (within 15 minutes prior to the beginning of the study drug infusion) and within 15 minutes after the end of the study drug infusion for each cycle during the Neoadjuvant Period. After the completion of treatment, an additional PK sample was collected at the EOT1.

Time frame:
End of each treatment cycles, up to 24 weeks (during neoadjuvant period)
Reported as:
Mean · µg/mL
Maximum Serum Concentration After Administration (Cmax) in Each Cycle
µg/mLCT-P6Herceptin
Cycle 1186.428 ± 69.0828178.567 ± 55.3800
Cycle 2145.078 ± 47.7899138.989 ± 45.7103
Cycle 3145.183 ± 44.5392141.130 ± 43.8189
Cycle 4148.541 ± 54.2737137.465 ± 45.6914
Cycle 5136.210 ± 44.6078135.307 ± 47.1950
Cycle 6143.569 ± 42.4510143.605 ± 51.2868
Cycle 7146.726 ± 48.0249141.468 ± 43.1823
Cycle 8145.081 ± 41.5382144.238 ± 57.3618
SecondaryTrough Serum Concentration (Ctrough) in Each Cycle

Pharmacokinetic samples were collected before study drug (CT-P6 or US-licensed Herceptin) administration (within 15 minutes prior to the beginning of the study drug infusion) and within 15 minutes after the end of the study drug infusion for each cycle during the Neoadjuvant Period. After the completion of treatment, an additional PK sample was collected at the EOT1.

Time frame:
Pre-infusion of cycles 1 to 8 during neoadjuvant period
Reported as:
Mean · µg/mL
Trough Serum Concentration (Ctrough) in Each Cycle
µg/mLCT-P6Herceptin
Cycle 118.915 ± 22.996418.905 ± 21.2967
Cycle 217.346 ± 17.977116.773 ± 16.8134
Cycle 316.796 ± 17.240917.816 ± 23.3438
Cycle 417.851 ± 20.157215.904 ± 15.8754
Cycle 518.403 ± 19.904217.962 ± 17.9429
Cycle 618.902 ± 20.219818.256 ± 17.6964
Cycle 718.540 ± 14.331318.718 ± 18.5976
Cycle 817.901 ± 7.220317.129 ± 10.0491
Post-hocThe Percentage of Patients Achieving Pathological Complete Response of the Breast and Axillary Nodes Regardless of DCIS

Subject who went through Neoadjuvant period completely (24 weeks), will receive surgery within 3-6 weeks after last treatment of neoadjuvant period. The secondary endpoint, other than pCR of breast and axillary nodes ragardless of DCIS which was primary endpoint, will be assessed using resected bio-specimens collected in breast and axilla during a surgery.

Time frame:
After Neo-adjuvant therapy and Surgery (up to 30 weeks)
Reported as:
Number · percentage of responders
The Percentage of Patients Achieving Pathological Complete Response of the Breast and Axillary Nodes Regardless of DCIS
percentage of respondersCT-P6Herceptin
The Percentage of Patients Achieving Pathological Complete Response of the Breast and Axillary Nodes Regardless of DCIS51.61 (45.20 to 57.98)55.08 (48.76 to 61.28)

Adverse events

Collected over Adverse events were assessed from the date the informed consent form is signed until up to 30 days from last dose of study drug, regardless of the relationship to the study drug. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CT-P6—22/271 (8.1%)263/271 (97%)
Herceptin—36/278 (12.9%)264/278 (95%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventCT-P6Herceptin
Febrile neutropeniaBlood and lymphatic system disorders6/2713/278
AnemiaBlood and lymphatic system disorders1/2713/278
NeutropeniaBlood and lymphatic system disorders2/2713/278
PneumoniaInfections and infestations2/2711/278
Device related infectionInfections and infestations0/2712/278
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2712/278
Adams-Stokes syndromeCardiac disorders1/2710/278
Abdominal painGastrointestinal disorders1/2710/278
Pancreatitis acuteGastrointestinal disorders1/2710/278
StomatitisGastrointestinal disorders1/2710/278
Most frequent other events
Showing 10 of 33
Most frequent other events
EventCT-P6Herceptin
AlopeciaSkin and subcutaneous tissue disorders196/271213/278
NeutropeniaBlood and lymphatic system disorders95/271116/278
NauseaGastrointestinal disorders99/27194/278
AnaemiaBlood and lymphatic system disorders59/27167/278
FatigueGeneral disorders53/27162/278
DiarrhoeaGastrointestinal disorders52/27150/278
AstheniaGeneral disorders47/27138/278
StomatitisGastrointestinal disorders46/27133/278
LeukopeniaBlood and lymphatic system disorders28/27141/278
ArthralgiaMusculoskeletal and connective tissue disorders34/27140/278

Baseline characteristics

Age, Continuous
Age, Continuous(years)CT-P6HerceptinTotal
Median53.0 (24 to 79)52.5 (22 to 74)53.0 (22 to 79)
Sex: Female, Male
Sex: Female, Male(Participants)CT-P6HerceptinTotal
Female278284562
Male000
08

Study locations

98 sites
  • Buenos Aires, 1185, Argentina
  • Córdoba, X5006IKK, Argentina
  • Quilmes, B1878DVB, Argentina
  • Rosario, S2000KDS, Argentina
  • San Salvador De Jujuy, 4600, Argentina
  • Santa Rosa, 6300, Argentina
  • Brest, 224027, Belarus
  • Minsk, 220013, Belarus
  • Minsk, 223040, Belarus
  • Sarajevo, 71000, Bosnia and Herzegovina
  • Santiago, 6640166, Chile
  • Temuco, 4810469, Chile
  • Nancy, 54511, France
  • Tbilisi, 0112, Georgia
  • Tbilisi, 0144, Georgia
  • Tbilisi, 0159, Georgia
  • Tbilisi, 0177, Georgia
  • Tbilisi, 0186, Georgia
  • Budapest, 1083, Hungary
  • Debrecen, 4032, Hungary
  • Bangalore, 560099, India
  • Chennai, 600017, India
  • Chennai, 600035, India
  • Delhi, 110095, India
  • Jaipur, 302017, India
  • Kolkata, 700016, India
  • Mumbai, 400 012, India
  • Nashik, 422004, India
  • Nashik, 422005, India
  • New Delhi, 110076, India
  • Pune, 411001, India
  • Bari, 70124, Italy
  • Pavia, 27100, Italy
  • Piacenza, 29100, Italy
  • Rimini, 47900, Italy
  • Tokyo, Japan
  • Daugavpils, LV-5417, Latvia
  • Riga, LV-1079, Latvia
  • Acapulco, 39670, Mexico
  • Monterrey, 64710, Mexico
  • Arequipa, 4020, Peru
  • Arequipa, Peru
  • Lima, 34, Peru
  • Trujillo, Peru
  • Cebu, 6000, Philippines
  • Makati, 1229, Philippines
  • Manila, 1008, Philippines
  • Pasig, 1600, Philippines
  • Quezon City, 1102, Philippines
  • San Juan City, 1502, Philippines
  • Taguig, 1634, Philippines
  • Gdansk, 80219, Poland
  • Lodz, 93513, Poland
  • Warsaw, 04125, Poland
  • Lisbon, 1099023, Portugal
  • Brasov, 500152, Romania
  • Bucharest, 010976, Romania
  • Bucharest, 022328, Romania
  • Cluj-Napoca, 400015, Romania
  • Cluj-Napoca, 400058, Romania
  • Suceava, 720237, Romania
  • Arkhangelsk, 163045, Russian Federation
  • Kazan, 420029, Russian Federation
  • Krasnoyarsk, 660133, Russian Federation
  • Kursk, 305035, Russian Federation
  • Moscow, 115478, Russian Federation
  • Moscow, 143423, Russian Federation
  • Nizhny Novgorod, 603081, Russian Federation
  • Novosibirsk, 630099, Russian Federation
  • Obninsk, 249036, Russian Federation
  • Omsk, Russian Federation
  • Samara, 443066, Russian Federation
  • Saransk, 430032, Russian Federation
  • St. Petersburg, 188663, Russian Federation
  • St. Petersburg, 194017, Russian Federation
  • St. Petersburg, 197022, Russian Federation
  • St. Petersburg, 197758, Russian Federation
  • Cape Town, 7570, South Africa
  • George, 6530, South Africa
  • Johannesburg, 2193, South Africa
  • Johannesburg, 2196, South Africa
  • Port Elizabeth, 6045, South Africa
  • Pretoria, 0002, South Africa
  • Sevilla, 41071, Spain
  • Zaragoza, 50009, Spain
  • Kaohsiung, 807, Taiwan
  • Taichung City, 40447, Taiwan
  • Taipei, 100, Taiwan
  • Cherkasy, 18009, Ukraine
  • Donetsk, 83092, Ukraine
  • Kharkiv, 61070, Ukraine
  • Kherson, 73000, Ukraine
  • Khmel'nyts'kyy, 29000, Ukraine
  • Poltava, 36021, Ukraine
  • Sumy, 40022, Ukraine
  • Uzhhorod, 88014, Ukraine
  • Vinnytsya, 21029, Ukraine
  • Zaporizhzhia, 69040, Ukraine
09

References and documents

Publications

  • Stebbing J, Baranau YV, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Pikiel J, Eniu AE, Li RK, Tiangco B, Lee SJ, Kim S. Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial. Breast Cancer Res Treat. 2021 Aug;188(3):631-640. doi: 10.1007/s10549-021-06240-5. Epub 2021 Jun 20. PubMed 34148205 ↗
  • Esteva FJ, Baranau YV, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskiy D, Pikiel J, Eniu AE, Li RK, Rusyn AV, Tiangco B, Lee SJ, Lee SY, Yu SY, Stebbing J. Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial. Cancer Chemother Pharmacol. 2019 Oct;84(4):839-847. doi: 10.1007/s00280-019-03920-4. Epub 2019 Aug 19. PubMed 31428820 ↗
  • Stebbing J, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskii D, Pikiel J, Eniu A, Komov D, Morar-Bolba G, Li RK, Rusyn A, Lee SJ, Lee SY, Esteva FJ. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol. 2017 Jul;18(7):917-928. doi: 10.1016/S1470-2045(17)30434-5. Epub 2017 Jun 4. Erratum In: Lancet Oncol. 2017 Aug;18(8):e433. doi: 10.1016/S1470-2045(17)30529-6. Lancet Oncol. 2017 Sep;18(9):e510. doi: 10.1016/S1470-2045(17)30637-X. PubMed 28592386 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2014 to primary completion in May 2016, 23 months.

Results were first posted in Oct 2019, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2014
First posted
Jun 13, 2014
StartActual
Jun 2014
Primary completionActual
May 26, 2016
CompletionActual
Oct 2018
Results first posted
Oct 29, 2019
Last update
Aug 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02162667
Lead sponsor
Celltrion
Collaborators
Nippon Kayaku Co., Ltd.
Responsible party
Sponsor
First posted
Jun 13, 2014
Start date
Jun 2014
Primary completion
May 26, 2016
Completion
Oct 2018
Results posted
Oct 29, 2019
Last update
Aug 3, 2022

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion